M&A / Deals UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies PharmaTimesPartnership builds on existing collaboration and adds two new UCBnominated projectsOncologyRead full story pharminent May 7, 2026 (Last updated: May 8, 2026) PharmaTimes Partnership builds on existing collaboration and adds two new UCBnominated projects Oncology Read full story Post navigation Previous: Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturingNext: Roche buys AI-powered diagnostics player PathAI Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026